Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
November 28 2023 - 7:00AM
Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage
biopharmaceutical company focused on developing small molecules to
restore neuronal health and slow neurodegeneration, today announced
that a symposium presentation highlighting data from preclinical
studies of ATH-1105 as a potential treatment candidate for
amyotrophic lateral sclerosis (ALS) will be delivered at the
upcoming Motor Neurone Disease Association (MNDA) 34th
International Symposium on ALS/MND, to be held December 6 – 8, 2023
in Basel, Switzerland.
Presentation Details:
Title: ATH-1105, a small molecule positive
modulator of the neurotrophic hepatocyte growth factor system, is
neuroprotective when administered prophylactically, therapeutically
or in combination with riluzole in the prp-TDP-43 A315T mouse model
of ALSSession: 6A: Preclinical Therapeutic
StrategiesSymposium Number:
C57Date/Time: Thursday, December 7, 12:15 – 12:30
p.m. CETPresenter: Kevin Church, Ph.D., Chief
Scientific Officer, Athira Pharma
“We look forward to the presentation of these data, which
highlight the potential of ATH-1105 as a treatment for ALS and add
to the growing body of scientific and clinical data that support
the potential benefits of our small molecule therapeutic candidates
targeting the neurotrophic HGF system as novel treatments for
neurodegenerative diseases,” stated Mark Litton, Ph.D., President
and Chief Executive Officer of Athira. “These data, which include
preclinical data showing prolonged survival and demonstrating
consistent improvements in motor function, nerve function,
biomarkers and nerve morphology in a transgenic mouse model of ALS,
strongly support confidence in our plans to advance this program
into human clinical studies in the first half of 2024.”
The presentation is available on the Scientific Publications
& Presentations page of the company’s website
at www.athira.com.
About ATH-1105ATH-1105 is an orally
administered small molecule designed to positively modulate the
neurotrophic hepatocyte growth factor (HGF) system, which plays a
critical role in nervous system maintenance and repair, including
stimulation of cell survival, increase in neuronal outgrowth and
modulation of neuronal network repair. In preclinical models of
amyotrophic lateral sclerosis (ALS), ATH-1105 has been shown to
significantly increase survival and delay time to death, enhance
motor and nerve function, reduce motor neuron demyelination and
axon degeneration, and improve biomarkers of neurodegeneration and
inflammation.
About Athira Pharma, Inc.Athira Pharma, Inc.,
headquartered in the Seattle, Washington area, is a late
clinical-stage biopharmaceutical company focused on developing
small molecules to restore neuronal health and slow
neurodegeneration. Athira aims to alter the course of neurological
diseases by advancing its pipeline of therapeutic candidates
targeting the neurotrophic HGF system for Alzheimer’s and
Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic
lateral sclerosis. For more information, visit www.athira.com.
You can also follow Athira on Facebook, LinkedIn, X (formerly known
as Twitter) and Instagram.
Forward-Looking StatementsThis communication
contains “forward-looking statements” within the meaning of Section
27A of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934 and the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are not based on
historical fact and include statements regarding: product
candidates as a potential treatment for Alzheimer’s disease,
Parkinson’s disease, Dementia with Lewy bodies, and other
neurodegenerative diseases, such as amyotrophic lateral sclerosis;
expectations regarding the potential efficacy and commercial
potential of Athira’s product candidates; and Athira’s ability to
advance its product candidates into later stages of development.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,” “on
track,” “would,” “expect,” “plan,” “believe,” “intend,” “pursue,”
“continue,” “suggest,” “potential,” and other similar expressions,
among others. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, the data from
preclinical and clinical trials may not support the safety,
efficacy and tolerability of Athira’s product candidates;
development of product candidates may cease or be delayed;
regulatory authorities could object to protocols, amendments and
other submissions; future potential regulatory milestones for
product candidates, including those related to current and planned
clinical studies, may be insufficient to support regulatory
submissions or approval; Athira may not be able to recruit
sufficient patients for its clinical trials; the outcome of legal
proceedings that have been or may in the future be instituted
against Athira, its directors and officers; possible negative
interactions of Athira's product candidates with other treatments;
Athira’s assumptions regarding the sufficiency of its cash, cash
equivalents and investments to fund its planned operations may be
incorrect; adverse conditions in the general domestic and global
economic markets; the impact of competition; regulatory agencies
may be delayed in reviewing, commenting on or approving any of
Athira’s clinical development plans as a result of pandemics or
health epidemics, which could further delay development timelines;
the impact of expanded product development and clinical activities
on operating expenses; the impact of new or changing laws and
regulations; as well as the other risks detailed in Athira’s
filings with the Securities and Exchange Commission from time to
time. These forward-looking statements speak only as of the date
hereof and Athira undertakes no obligation to update
forward-looking statements. Athira may not actually achieve the
plans, intentions, or expectations disclosed in its forward-looking
statements, and you should not place undue reliance on the
forward-looking statements.
Investor & Media ContactJulie RathbunAthira
PharmaJulie.rathbun@athira.com 206-769-9219
Athira Pharma (NASDAQ:ATHA)
Historical Stock Chart
From Apr 2024 to May 2024
Athira Pharma (NASDAQ:ATHA)
Historical Stock Chart
From May 2023 to May 2024